About this publication, and how it earns
Who publishes Exosomal Therapy, what it is for, how it makes money, and the things it will not do at any price.
What this is
Exosomal Therapy is a science desk covering extracellular vesicles and the regenerative aesthetics category built around them. It is published by Northbank Media, which publishes independent specialist titles.
The editorial position is straightforward. The underlying biology is real and interesting. The commercial claims made on top of it usually run well ahead of the evidence. Both of those statements can be true at once, and a publication that holds them together is more useful than one that picks a side.
We are not a clinic. We treat nobody, diagnose nobody and recommend no procedure to any individual. We sell no product, hold no stock, take no commission on any treatment, and receive no payment from any manufacturer, distributor or clinic in connection with editorial content.
Who it is for
Two audiences, and we do not write down to either. A clinically literate reader who wants the mechanism and the methodological problems stated properly. And a curious patient who has been told something confident in a consultation and wants to know how much of it is established.
The compromise we make for both is to explain terms at first use, in the term boxes collected in the glossary, rather than either assuming knowledge or omitting the substance.
How this publication earns money
Plainly, because a publication that grades commercial claims owes its readers an account of where its own money comes from. There are two revenue lines and no others.
Paid listings
Suppliers and clinics may pay to appear in the listings. A listing contains only verifiable, disclosed facts about sourcing, regulatory status and provenance. Listings are ordered alphabetically, never ranked, and every listing carries a paid label on every appearance. Where a listed party declines to disclose one of the standard fields, we publish that they declined.
A listing is not an endorsement, is not a recommendation, and cannot influence an evidence grade, an article, or whether a claim is covered. We do not offer, and will not create, a premium position, a featured slot, an ordering preference or a badge.
The science briefing
Our newsletter carries one labelled sponsor line at the foot of each issue. The sponsor line is a sponsor line and nothing else. It buys no mention in the editorial content of the issue, no influence over what is covered, and no sight of the issue before it is sent. Rates are published on the rate card.
What we do not do
- No advertising network, no programmatic display, no paid search arbitrage.
- No affiliate links. Nothing on this site earns us a commission if you click it.
- No sponsored articles, advertorial, or content written or reviewed by a commercial party.
- No paid placement inside editorial, including inside comparison tables.
- No sale, rental or sharing of subscriber data.
The line that cannot be crossed
No commercial arrangement can influence an evidence grade. This is the only thing this publication actually sells, in the sense that it is the only thing readers have to trust, and it is therefore the one thing that is not for sale. We publish what we refuse at any price on the rate card, so that the refusals are as visible as the offers.
Corrections
We correct errors and we say what changed. Where a grade moves, we record the evidence that moved it against the line in the original panel that named what we were waiting for. Write to desk@exosomaltherapy.co.uk with a citation and we will read it.
Our own interests, declared
A publication built around a grading device has an interest in the device looking useful, and therefore an interest in claims being gradeable. We mitigate that by using NOT ASSESSABLE where a claim cannot be tested as worded, rather than forcing it onto the scale, and every panel is public so readers can check whether we do so consistently.
We also have an interest in this category remaining interesting enough to write about. We do not think that biases us towards credulity, but a reader is entitled to know the incentive exists rather than to be told there is none.
Questions readers ask
Who publishes Exosomal Therapy?
Northbank Media, which publishes independent specialist titles. This title is its science desk for regenerative aesthetics.
Do you sell products or treatments?
No. We hold no stock, take no commission on any treatment, and receive no payment from any manufacturer, distributor or clinic in connection with editorial content.
Can a company pay for a better evidence grade?
No. No commercial arrangement of any kind can influence a grade, an article, a correction or whether a claim is covered. What we refuse at any price is published on the rate card.
Do you use affiliate links?
No. Nothing on this site earns a commission if you click it, and we do not run advertising networks or programmatic display.
How do I report an error?
Write to desk@exosomaltherapy.co.uk with a citation. We correct errors, say what changed, and where a grade moves we record the evidence that moved it against the line in the original panel.
The science briefing
One email a fortnight. What was published in extracellular vesicle and regenerative aesthetics research, what it actually showed, and which claims moved on our grading scale. Written for people who read the methods section.
No spam, unsubscribe in one click. We never pass your address to a third party. See privacy.
Sponsor slot Each issue carries one labelled sponsor line at the foot. Sponsorship buys that line and nothing else. It cannot influence an evidence grade, a correction, or whether a claim is covered. Rate card and refusals.